Literature DB >> 22941170

Influence of nonclinical factors on choice of therapy for early hepatocellular carcinoma.

Hari Nathan1, Dorry L Segev, John F P Bridges, Allan B Massie, Andrew M Cameron, Kenzo Hirose, Richard D Schulick, Michael A Choti, Timothy M Pawlik.   

Abstract

BACKGROUND: Initial therapy for early hepatocellular carcinoma (HCC) with well-compensated cirrhosis is controversial. While we previously reported on the effect of clinical factors and surgeon specialty on choice of therapy for early HCC, other nonclinical factors also may impact decision-making.
METHODS: Surgeons who treat HCC were invited to complete a web-based survey that included ten case scenarios. Choice of therapy-liver transplantation (LT), liver resection (LR), or radiofrequency ablation (RFA)-was analyzed using regression models.
RESULTS: There were 336 responses for analysis. Most respondents were in academic centers (86 %) that offered LT (71 %). The median number of patients annually evaluated for HCC was 30. Both practice type and HCC case volume were associated with choice of therapy, but these associations were not independent of surgeon specialty. LT surgeons who did not also perform RFA were less likely than those LT surgeons who did offer RFA to choose RFA over LT (relative risk ratios (RRR) 0.38, P < 0.001). Non-LT surgeons were more likely than LT surgeons who also offered RFA to choose RFA over LT (RRR 2.24, P < 0.001). Surgeons who worked at hospitals where LT was performed were much more likely to choose LT over LR and RFA even if they did not personally perform LT (RRR 1.27 and RRR 3.33, P < 0.001).
CONCLUSIONS: Surgeon- and institution-related factors impact choice of therapy for early HCC even after adjustment for differences in clinical presentation. These data suggest that choice of therapy for patients with early HCC varies across providers independent of case selection.

Entities:  

Mesh:

Year:  2012        PMID: 22941170     DOI: 10.1245/s10434-012-2619-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  14 in total

1.  Disparities in care for patients with curable hepatocellular carcinoma.

Authors:  Richard S Hoehn; Dennis J Hanseman; Peter L Jernigan; Koffi Wima; Audrey E Ertel; Daniel E Abbott; Shimul A Shah
Journal:  HPB (Oxford)       Date:  2015-09       Impact factor: 3.647

2.  Assessing resectability of colorectal liver metastases: How do different subspecialties interpret the same data?

Authors:  Jean-Michel Aubin; Alexsander K Bressan; Sean C Grondin; Elijah Dixon; Anthony R MacLean; Sean Gregg; Patricia Tang; Gilaad G Kaplan; Guillaume Martel; Chad G Ball
Journal:  Can J Surg       Date:  2018-08       Impact factor: 2.089

3.  Locoregional therapy as a bridge to liver transplantation for hepatocellular carcinoma within Milan criteria: from a transplant oncology viewpoint.

Authors:  Taizo Hibi; Yasuhiko Sugawara
Journal:  Hepatobiliary Surg Nutr       Date:  2018-04       Impact factor: 7.293

4.  Multidisciplinary clinic in the management of hepatocellular carcinoma.

Authors:  Kevin C Soares; David C Cosgrove; Joseph M Herman; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2013-12-07       Impact factor: 5.344

5.  Referral patterns and treatment choices for patients with hepatocellular carcinoma: a United States population-based study.

Authors:  Omar Hyder; Rebecca M Dodson; Hari Nathan; Joseph M Herman; David Cosgrove; Ihab Kamel; Jean-Francois H Geschwind; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2013-09-13       Impact factor: 6.113

Review 6.  Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun.

Authors:  Taizo Hibi; Osamu Itano; Masahiro Shinoda; Yuko Kitagawa
Journal:  Surg Today       Date:  2016-04-29       Impact factor: 2.549

7.  Temporal trends in population-based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years.

Authors:  Yuhree Kim; Aslam Ejaz; Amit Tayal; Gaya Spolverato; John F P Bridges; Robert A Anders; Timothy M Pawlik
Journal:  Cancer       Date:  2014-06-10       Impact factor: 6.860

Review 8.  Current status of the organ replacement approach for malignancies and an overture for organ bioengineering and regenerative medicine.

Authors:  Taizo Hibi; Masahiro Shinoda; Osamu Itano; Yuko Kitagawa
Journal:  Organogenesis       Date:  2014-05-16       Impact factor: 2.500

9.  Patterns of consultation and treatment of patients with hepatocellular carcinoma presenting to a large academic medical center in the US.

Authors:  Sylvie Stacy; Omar Hyder; David Cosgrove; Joseph M Herman; Ihab Kamel; Jean-Francois H Geschwind; Ahmet Gurakar; Robert Anders; Andrew Cameron; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2013-06-19       Impact factor: 3.452

10.  Assessing resectability of colorectal liver metastases: How do different subspecialties interpret the same data?

Authors:  Jean-Michel Aubin; Alexsander K Bressan; Sean C Grondin; Elijah Dixon; Anthony R MacLean; Sean Gregg; Patricia Tang; Gilaad G Kaplan; Guillaume Martel; Chad G Ball
Journal:  Can J Surg       Date:  2018-06-01       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.